Scarica l'app Stockscreener
7.10
0.28%
-0.02
Dopo l'orario di chiusura:
7.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Franklin Resources Inc. Raises Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
Charles Schwab Investment Management Inc. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Down 6.4% in November - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Analysts - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 6.4%Here's Why - MarketBeat
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
EyePoint reports inducement grants under NASDAQ listing rule - Yahoo Finance
EyePoint Pharmaceuticals to Present at JP Morgan Healthcare Conference 2025 - StockTitan
EYPT stock touches 52-week low at $7.4 amid market challenges - Investing.com Canada
Short Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Decreases By 6.4% - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Sets New 52-Week LowHere's Why - MarketBeat
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards Strategic Stock Options to Expand Leadership Team - StockTitan
When the Price of (EYPT) Talks, People Listen - Stock Traders Daily
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk - Simply Wall St
EyePoint begins dosing in second global Phase 3 LUCIA clinical trial of Duravyu for the treatment of wet AMD - Optometry Times
EyePoint Pharmaceuticals (FRA:PV3B) 5-Year Sortino Ratio : 1.27 (As of Dec. 09, 2024) - GuruFocus.com
Point72 Asset Management L.P. Sells 179,451 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
Intech Investment Management LLC Invests $136,000 in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals’ (EYPT) “Buy” Rating Reiterated at HC Wainwright - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 7%Still a Buy? - MarketBeat
EyePoint Pharmaceuticals Insiders Sold US$935k Of Shares Suggesting Hesitancy - Simply Wall St
EyePoint Pharmaceuticals (STU:PV3B) PS Ratio : 9.30 (As of Dec. 05, 2024) - GuruFocus.com
EyePoint doses first patient in second Phase 3 LUCIA clinical trial - Yahoo Finance
EyePoint advances wet AMD treatment with new trial By Investing.com - Investing.com Canada
Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration - Marketscreener.com
Patient Square Capital LP Acquires New Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint advances wet AMD treatment with new trial - Investing.com
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration - The Manila Times
EyePoint Launches Landmark Phase 3 Trial for Revolutionary 6-Month Eye Disease Treatment - StockTitan
How To Trade (EYPT) - Stock Traders Daily
EYPT (EyePoint Pharmaceuticals) Median PS Value : $7.51 (As of Dec. 01, 2024) - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Sells 71,796 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EYPT (EyePoint Pharmaceuticals) 3-Year Revenue Growth Rate : -23.90% (As of Sep. 2024) - GuruFocus.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
EYPT (EyePoint Pharmaceuticals) Degree of Operating Leverage : 0.73 (As of Sep. 2024) - GuruFocus.com
EYPT (EyePoint Pharmaceuticals) Enterprise Value : $396.54 Mil (As of Nov. 20, 2024) - GuruFocus.com
EyePoint Pharmaceuticals (FRA:PV3B) Enterprise Value : €374.46 Mil (As of Nov. 20, 2024) - GuruFocus.com
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? - MSN
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
EyePoint Pharmaceuticals Awards 23,600 Stock Options to New Employees at $9.17 | EYPT Stock News - StockTitan
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 8.5%Here's What Happened - MarketBeat
EyePoint Pharmaceuticals : Announces $16.5 Million Monetization of ILUVIEN Royalty with SWK Holdings Corporation - Marketscreener.com
HC Wainwright Has Pessimistic View of EYPT FY2024 Earnings - MarketBeat
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha
EyePoint price target lowered to $33 from $38 at Baird - Yahoo Finance
(EYPT) Technical Data - Stock Traders Daily
EyePoint Pharmaceuticals Reports $29.4 Million Third Quarter Net Loss - Vision Monday
EyePoint shares retain Outperform as Baird sees upside in DME and wet AMD opportunities - Investing.com
EyePoint Pharmaceuticals, Inc.’s US$161 Million Public Offering Of Common Stock - Global Legal Chronicle
H.C. Wainwright trims EyePoint stock target, highlights cash runway extension to 2027 - Investing.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $22.00 by Analysts at HC Wainwright - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $33.00 by Analysts at Robert W. Baird - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):